Published in Addict Sci Clin Pract on December 01, 2007
Response: a case for collaborative care. Addict Sci Clin Pract (2007) 0.75
Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med (2002) 36.55
Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet (2001) 35.17
Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. Centers for Disease Control and Prevention. MMWR Recomm Rep (1998) 12.78
The natural history of hepatitis C virus infection: host, viral, and environmental factors. JAMA (2000) 7.65
National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C: 2002--June 10-12, 2002. Hepatology (2002) 5.16
Sharing of drug preparation equipment as a risk factor for hepatitis C. Am J Public Health (2001) 4.57
Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis c. J Hepatol (2001) 3.64
Routes of infection, viremia, and liver disease in blood donors found to have hepatitis C virus infection. N Engl J Med (1996) 2.79
Treatment with pegylated interferon and ribavarin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study. Hepatology (2004) 2.50
Similar compliance and effect of treatment in chronic hepatitis C resulting from intravenous drug use in comparison with other infection causes. Eur J Gastroenterol Hepatol (2006) 2.47
Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastroenterology (2005) 2.19
Hepatitis C virus infection in the United States. J Hepatol (1999) 2.03
Prevention and treatment of hepatitis C in injection drug users. Hepatology (2002) 1.88
Treatment of hepatitis C infection in injection drug users. Hepatology (2001) 1.87
The importance of preventing hepatitis C virus infection among injection drug users in the United States. J Acquir Immune Defic Syndr Hum Retrovirol (1998) 1.68
Progression of liver fibrosis among injection drug users with chronic hepatitis C. Hepatology (2006) 1.63
A prospective controlled study of interferon-based therapy of chronic hepatitis C in patients on methadone maintenance. Hepatology (2004) 1.52
10-Year follow-up after interferon-alpha therapy for chronic hepatitis C. Hepatology (1998) 1.44
Hepatitis C and alcohol. Hepatology (1997) 1.36
Treatment of chronic hepatitis C in injecting drug users: 5 years' follow-up. Eur Addict Res (2002) 1.35
Treatment of hepatitis C. Am J Med (2005) 1.35
The impact of barriers to hepatitis C virus treatment in recovering heroin users maintained on methadone. J Subst Abuse Treat (2005) 1.22
Infrequent reinfection after successful treatment for hepatitis C virus infection in injection drug users. Clin Infect Dis (2004) 1.10
Treatment with interferon-alpha in patients with chronic hepatitis and mood or anxiety disorders. Lancet (1999) 1.09
A prospective, community-based evaluation of liver enzymes in individuals with hepatitis C after drug use. Hepatology (1999) 1.03
Interferon-alpha can be used successfully in patients with hepatitis C virus-positive chronic hepatitis who have a psychiatric illness. Eur J Gastroenterol Hepatol (1995) 1.02
Neuropsychiatric toxicity of antiviral treatment in chronic hepatitis C. Dig Dis (2000) 0.92
Hepatitis C Virus Infection in HIV-infected Patients. Curr Infect Dis Rep (2001) 0.92
Neuropsychiatric side effects of HCV therapy and their treatment: focus on IFN alpha-induced depression. Gastroenterol Clin North Am (2004) 0.90
Treating hepatitis C: the state of the art. Gastroenterol Clin North Am (2004) 0.87